International Journal of Enhanced Research in Medicines & Dental Care (IJERMDC),
ISSN: 2349-1590, Vol. 12 Issue 11, November 2025

Host Modulation Therapy in Periodontics: A Comprehensive Review

Anjali Yadav[1], Sushma Kumari[2], Priyanka Chandela[3]

[1,2,3]Resident, Department of periodontology, Post Graduate Institute of Dental Sciences, Rohtak.

ABSTRACT

Host Modulation Therapy (HMT) represents a novel and evolving approach in the management of chronic inflammatory diseases, particularly periodontitis. Unlike traditional antimicrobial and mechanical therapies that primarily target pathogenic microorganisms, HMT focuses on modifying the host's immune-inflammatory response to prevent excessive tissue destruction and promote healing. This review summarizes the biological basis, therapeutic agents, clinical applications, and future directions of host modulation therapy, with special emphasis on its role in periodontal disease management.

Keywords: Host modulation therapy, Periodontitis, Matrix metalloproteinases, Nonsteroidal anti-inflammatory drugs, Subantimicrobial doxycycline, Cytokine modulation.

INTRODUCTION

Periodontal diseases are chronic inflammatory conditions initiated by microbial plaque biofilms but perpetuated and aggravated by the host's exaggerated immune response. The destruction of periodontal tissues, including connective tissue attachment and alveolar bone, is largely mediated by inflammatory cytokines, prostaglandins, and matrix metalloproteinases (MMPs). Traditional therapies such as scaling and root planing (SRP) primarily target bacterial reduction but fail to adequately address the host-mediated tissue breakdown.

The concept of Host Modulation Therapy (HMT) emerged to counteract this limitation by aiming to modify or regulate the host's immune-inflammatory response, thereby restoring the balance between pro-inflammatory and anti-inflammatory mediators. Introduced in the 1990s, HMT has since become an important adjunct to conventional periodontal therapy.

2. Rationale for Host Modulation

The host response plays a dual role in periodontal disease: while it is essential for controlling microbial infection, an exaggerated or prolonged response can lead to tissue destruction. The pathogenesis of periodontitis involves an imbalance between pro-inflammatory and anti-inflammatory mediators.

Key mechanisms contributing to tissue breakdown include overproduction of pro-inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), excessive synthesis of prostaglandins (notably PGE_2), promoting osteoclast activity and bone resorption, increased activity of matrix metalloproteinases (MMPs), leading to degradation of extracellular matrix and collagen fibers and oxidative stress and generation of reactive oxygen species (ROS), damaging cellular components.

Host modulation strategies aim to reduce destructive pathways and enhance protective, regenerative mechanisms, creating a more favorable environment for tissue repair and regeneration.

3. Mechanisms of Host Modulation

Host modulation can be achieved through various mechanisms:

1. Inhibition of destructive enzymes: Drugs such as subantimicrobial-dose doxycycline inhibit MMPs responsible for collagen degradation.
2. Regulation of inflammatory mediators: Agents like nonsteroidal anti-inflammatory drugs (NSAIDs) reduce prostaglandin production and attenuate bone resorption.

3. Modulation of cytokine activity: Biologic agents (e.g., monoclonal antibodies) can neutralize pro-inflammatory cytokines like TNF-α or IL-1β.
4. Promotion of bone metabolism: Bisphosphonates and hormone replacement therapies help reduce bone loss and maintain alveolar bone density.
5. Antioxidant and nutraceutical approaches: Natural compounds such as curcumin, resveratrol, and omega-3 fatty acids exhibit anti-inflammatory and antioxidant properties.

4. Pharmacologic Agents in Host Modulation Therapy

4.1 Subantimicrobial-Dose Doxycycline (SDD)

Doxycycline, a tetracycline derivative, at low doses (20 mg twice daily), exerts anti-collagenolytic effects independent of its antimicrobial activity. It inhibits MMP-8 and MMP-9, which are key enzymes in connective tissue breakdown. Mechanism of Action include inhibition of MMPs and pro-MMP activation, suppression of cytokine production (IL-1β, TNF-α), reduction in oxidative stress.

4.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs such as ibuprofen and flurbiprofen inhibit cyclooxygenase (COX) enzymes, thus reducing PGE_2 synthesis and preventing alveolar bone resorption. Advantages are decrease in gingival inflammation, reduced rate of bone loss in short-term studies. Limitations are long-term systemic use is limited due to gastrointestinal, renal, and cardiovascular effects,discontinuation often leads to rebound bone loss. Topical or localized delivery systems are under investigation to mitigate systemic toxicity.

4.3 Bisphosphonates

These pyrophosphate analogs inhibit osteoclast-mediated bone resorption. Alendronate and etidronate have shown promise in preserving alveolar bone density. Long-term use may be associated with osteonecrosis of the jaw (ONJ), particularly following dental extractions or trauma.

4.4 Anti-Cytokine and Biologic Therapies

Monoclonal antibodies and receptor antagonists have been developed to block the effects of pro-inflammatory cytokines. Examples are etanercept, infliximab: TNF-α inhibitors, anakinra: IL-1 receptor antagonist, tocilizumab: IL-6 receptor blocker. While these agents are primarily used in rheumatoid arthritis and other systemic conditions, research suggests potential benefits in severe, refractory periodontitis cases.

4.5 Nutraceuticals and Natural Modulators

Nutritional and herbal compounds have gained interest due to their minimal side effects and broad biological activity. Prominent agents include Omega-3 fatty acids reduce inflammation via pro-resolving lipid mediators (resolvins, protectins), curcumin inhibits NF-κB pathway and reduces oxidative stress, resveratrol exhibits anti-inflammatory and antioxidant properties, green tea catechins suppress MMP activity and bacterial adhesion.

5. Clinical Applications

Host modulation therapy is primarily used as an adjunct to conventional mechanical debridement in chronic periodontitis. Clinical studies have reported:

- Reduced pocket depth and improved attachment levels.
- Decreased gingival inflammation and bleeding on probing.
- Lowered levels of systemic inflammatory markers, linking periodontal therapy to systemic health benefits.

HMT may also have applications in systemic conditions with an inflammatory component, such as diabetes mellitus, rheumatoid arthritis, and cardiovascular disease.

6. Future Perspectives

The future of host modulation lies in precision medicine, where genetic and molecular profiling could guide individualized treatment strategies. Nanotechnology-based drug delivery systems, gene therapy, and novel biologic agents targeting specific inflammatory pathways represent exciting frontiers. Moreover, combining HMT with regenerative therapies may further enhance clinical outcomes.

CONCLUSION

Host modulation therapy represents a significant advancement in the management of periodontal diseases by addressing the underlying host response rather than solely focusing on microbial control. While sub-antimicrobial dose doxycycline

remains the most established agent, ongoing research into biologic and natural modulators continues to expand the therapeutic landscape. Integrating HMT into periodontal care can improve long-term stability and may contribute to better systemic health outcomes.

REFERENCES

[1]. Joseph R, Amarnath V. Host modulation therapy in periodontics – A review. Asian J Pharm Health Sci. 2015;5(2):1262-1266.
[2]. Shinwari MS, Tanwir F, Raza Hyder P, Bin Saeed MH. Host Modulation Therapeutics in Periodontics: Role as an Adjunctive Periodontal Therapy. J Coll Physicians Surg Pak. 2014;24(9):676-684.
[3]. Alsakr A. Periodontal Diseases and Host Modulation Therapies. J Pharm Bioallied Sci. 2025;17(Suppl 3):S2052-S2054.
[4]. Golub LM, Lee HM. Periodontal therapeutics: Current host-modulation agents and future directions. Periodontol 2000. 2019;82(1):186-204. Joseph R, Amarnath V. Host-modulation therapy in periodontics – update on past and future agents. Asian J Pharm Health Sci. 2015;5(2).
[5]. SDCEP. Host modulation therapy. Prevention and Treatment of Periodontal Diseases in Primary Care. UK. (Cond. Rec.). 2024.
[6]. Shetty S, Alattas AH, Alsulaimani RJ, et al. Host Modulation Therapy with Short Term Use of Oral Omega-3 Fatty Acids as an Adjunct to Non-Surgical Periodontal Therapy – A Pilot Project. J Coastal Life Med. 2023;11(1):3229-3240.
[7]. Choi DH, Moon IS, Choi BK, et al. Effects of sub-antimicrobial dose doxycycline therapy on crevicular fluid MMP-8, gingival tissue MMP-9, TIMP-1 and IL-6 levels in chronic periodontitis. J Periodontal Res. 2004;39(1):20-26.
[8]. Engebretson SP, Hey-Hadavi J. Sub-antimicrobial doxycycline for periodontitis reduces HbA1c in subjects with type 2 diabetes: a pilot study. Pharmacol Res. 2011;64(6):624-629.
[9]. Robbins D, et al. Efficacy of sub-antimicrobial dose doxycycline in post-menopausal women: clinical outcomes. J Clin Periodontol. 2007;34(11):Apply.
[10]. Jaafer S S, Alasady M S, Hanfoosh H S. Evaluating the Efficacy of Sub-antimicrobial Dose Doxycycline in the Treatment of Periodontal Disease as Host Modulation. Am J Biomed Pharm. 2025;2.
[11]. Gaind S. Recent Host Modulation Therapy: A Mini Review. Global J Med Res. 2021;21(J2):27-30.
[12]. Bhoir V, Shetty D. Host Modulation Therapy: A review. IJDSIR. 2020;3(4):207-223.
[13]. Reddy H, Satyanarayana S, Vidya S, Surykanth M. Host Modulation Therapy – Restriction of Periodontal Destruction. Indian J Dent Adv. 2014;3(3):621.
[14]. Thahir H, Djais A I, Syukur F. The Role of Omega-3 as a Host Modulation Therapy (HMT) in Periodontal Tissue Regeneration: A Systematic Review. Malays J Med Health Sci. 2021;17:67-72.
[15]. Choi DH, Moon IS, et al. (Repeated for emphasis) Effects of SDD on MMPs.
[16]. Shinwari MS, Tanwir F, Raza Hyder P, Bin Saeed MH. (Repeated) Host Modulation Therapeutics in Periodontics.
[17]. Mohindra K, Nirola A. Host Modulation Review. Austin J Dent. 2017;4:1086.
[18]. "Host modulation as a therapeutic strategy in the treatment of periodontal disease." J Periodontol. 2002;73.
[19]. Salim J, et al. Chemically modified tetracyclines: the novel host modulating agents. J Ind Soc Periodontol. 2022.